Drugs / AAV9.SLC6A1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07173153 | Aug 2025 → Aug 2028 expected | inborn disorder of neurotransmitter metabolism and transport | Emily de los Reyes | Enrolling by invitation | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV9.SLC6A1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07173153 ↗ |
| Action | Restore | “Adeno-associated virus serotype 9-mediated gene replacement normalized electroencephalography abnormalities in preclinical models” PMID 42173049 ↗ May 2026 |
| Modality | Gene therapy (AAV / viral vector) | “Adeno-associated virus serotype 9-mediated gene replacement” PMID 42173049 ↗ May 2026 |
| Route | Intrathecal | “delivered one time through an intrathecal injection” NCT07173153 ↗ |
| Target | SLC6A1 | “Phase I/II Intrathecal Gene Delivery Clinical Trial of scAAV9.P546.SLC6A1 for SLC6A1 Neurodevelopmental Disorder” NCT07173153 ↗ |